Table 3.

Landmark analyses for OS by objective response in the overall REFLECT population

Firstauthor [ref.], year	Agents (study design)	ORR (mRECIST), % (95% CI) (n/total n)	Median OS, months (95% CI)		Landmark analyses, HR (95% CI)
Firstauthor [ref.], year	Agents (study design)	ORR (mRECIST), % (95% CI) (n/total n)	responder (CR + PR)	nonresponder (SD + PD)	2 months	4 months	6 months
Kudo [11], 2019	lenvatinib +sorafenib	16.7 (14.3–19.0)	22.4	11.4	0.75	0.72	0.73
	lenvatinib +sorafenib	(159/954)	(19.7–26.0)	(10.3–12.3)	(0.57–0.98)	(0.56–0.92)	(0.57–0.93)
	(phase 3 RCT)

OS, overall survival; RCT, randomized controlled trial; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio; CI, confidence interval.